Bleomycin revisited: towards a more representative model of IPF?
Scotton
Chris J
CJ
Chambers
Rachel C
RC
D000199:Actins / Q000378:metabolism; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity; D001761:Bleomycin / Q000633:toxicity; D004195:Disease Models, Animal; D005355:Fibrosis; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D006965:Hyperplasia; D054990:Idiopathic Pulmonary Fibrosis / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D020287:In Situ Nick-End Labeling; D007440:Intubation; D008168:Lung / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011650:Pulmonary Alveoli / Q000473:pathology; D011663:Pulmonary Surfactants / Q000378:metabolism; D000071999:S100 Calcium-Binding Protein A4; D009418:S100 Proteins / Q000378:metabolism; D014598:Uteroglobin / Q000378:metabolism
C558396:Acta2 protein, mouse; D000199:Actins; D000903:Antibiotics, Antineoplastic; D011663:Pulmonary Surfactants; D000071999:S100 Calcium-Binding Protein A4; D009418:S100 Proteins; C470944:S100a4 protein, mouse; C556389:SCGB1A1 protein, human; C556390:Scgb1a1 protein, mouse; D001761:Bleomycin; D014598:Uteroglobin